The U.S. Supreme Court denied Agilent’s request to review invalidation of two CRISPR-related patents, effectively ending the company’s multi-year legal fight with Synthego. Synthego said the decision leaves in place a June 2025 Federal Circuit ruling that upheld USPTO PTAB determinations that Agilent’s claims were unpatentable. The patents at issue relate to chemical modifications of guide RNAs used in CRISPR-Cas gene editing. Synthego’s narrative frames the outcome as removal of barriers to implementing gRNA modifications in CRISPR-enabled research and therapeutics. For gene-editing tools and platform developers, the ruling reduces uncertainty around freedom to operate and may impact licensing negotiations and procurement of modified gRNAs. It also underscores how quickly CRISPR IP landscapes can turn when PTAB decisions are affirmed through final appellate steps.